Krystal Biotech (KRYS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $1.79
- Estimate
- $1.91
- Surprise
- -6.5%
- Revenue (period 2026-06-30)
- $119.2M
- Score today
- 6.4/10
Revenue source: xbrl.
How the report landed
Krystal Biotech (KRYS) missed the $1.91 estimate with adjusted EPS of $1.79 — a clear 6.5% shortfall.
Where TrendMatrix's rating stands now
TrendMatrix currently rates KRYS Buy (Wait) at 6.4/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -6.5% surprise compares with a +41.3% four-quarter average. Next scheduled report: 2026-11-02.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.1 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: VYJUVEK
- Analyst target reached - limited upside remaining
- Expensive valuation
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $344.96
- Entry target
- $296.78
- Price target
- $365.84
- Stop
- $273.81
- Upside to target
- +6.1%
The stock trades at 44.0× trailing but 36.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
KRYS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $10.12B
- P/E (fwd)
- 36.7
- P/E (ttm)
- 44.0
- 52-week range
- $158.08–$382.54
- Off 52-week high
- 9.8%
- RSI (14)
- 32
- Volume vs avg
- 0.82×
- Score today
- 6.4/10